Nasdaq · Healthcare
Verrica Pharmaceuticals Inc. (VRCA)
As-reported financials and recent SEC filings for Verrica Pharmaceuticals Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$35.6M
Net income
$-17.9M
Net margin
-50.3%
Diluted EPS
$-1.68
ROE
-72.3%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M |
| Gross profit | — | $5.0M | $4.6M | — | — |
| Operating income | $-12.2M | $-65.9M | $-65.8M | $-21.3M | $-30.9M |
| Net income | $-17.9M | $-76.6M | $-67.0M | $-24.5M | $-35.1M |
| Diluted EPS | $-1.68 | $-7.39 | $-6.66 | $-3.24 | $-5.85 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →8-K2026-06-09
View on EDGAR →Largest Healthcare peers
Go deeper on VRCA
Search Verrica Pharmaceuticals Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.